About Cardio Diagnostics Holdings, Inc.
https://cardiodiagnosticsinc.comCardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
CEO
Meeshanthini V. Dogan
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 14, 2022
Method of going public SPAC
Full time employees 13
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 5
Overall Score 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $35611
52w High $0.02
52w Low $0.02
P/E 0
Volume 50.85K
Outstanding Shares 1.83M
About Cardio Diagnostics Holdings, Inc.
https://cardiodiagnosticsinc.comCardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.85K ▼ | $1.62M ▲ | $-1.71M ▼ | -60.05K% ▼ | $-0.98 ▼ | $-1.62M ▼ |
| Q2-2025 | $7.47K ▲ | $1.6M ▼ | $-1.68M ▼ | -22.52K% ▲ | $-0.97 | $-1.59M ▼ |
| Q1-2025 | $940 ▼ | $1.63M ▲ | $-1.64M ▼ | -173.94K% ▼ | $-0.97 ▼ | $-1.51M ▼ |
| Q4-2024 | $4.51K ▼ | $1.52M ▲ | $-1.52M ▼ | -33.67K% ▼ | $-0.06 ▲ | $-1.43M ▼ |
| Q3-2024 | $6.58K | $1.42M | $-1.41M | -21.47K% | $-1.73 | $-1.33M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.36M ▼ | $8.79M ▼ | $637.33K ▼ | $8.15M ▼ |
| Q2-2025 | $7.97M ▼ | $10.4M ▼ | $671.85K ▼ | $9.72M ▼ |
| Q1-2025 | $9.69M ▲ | $12.28M ▲ | $905K ▼ | $11.38M ▲ |
| Q4-2024 | $7.83M ▲ | $10.62M ▲ | $1.06M ▲ | $9.56M ▲ |
| Q3-2024 | $1.98M | $4.48M | $795.28K | $3.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.71M ▼ | $-1.39M ▲ | $-257.82K ▼ | $39.95K ▲ | $-1.61M ▲ | $-1.56M ▲ |
| Q2-2025 | $-1.68M ▼ | $-1.57M ▼ | $-35.72K ▲ | $-115.04K ▼ | $-1.72M ▼ | $-1.59M ▼ |
| Q1-2025 | $-1.64M ▼ | $-1.4M ▼ | $-47.41K ▲ | $3.31M ▼ | $1.86M ▼ | $-1.45M ▼ |
| Q4-2024 | $-1.52M ▼ | $-1.39M ▼ | $-54.61K ▲ | $7.29M ▲ | $5.84M ▲ | $-1.4M ▼ |
| Q3-2024 | $-1.41M | $-1.16M | $-78.57K | $1.91M | $672.47K | $-1.18M |
CEO
Meeshanthini V. Dogan
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 14, 2022
Method of going public SPAC
Full time employees 13
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 5
Overall Score 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0